Breaking News
Subscribe Now 0
📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI. See top stocks
Close

Pfizer Inc (PFE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
26.63 +0.65    +2.50%
14:00:59 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US7170811035 
S/N:  852009
  • Volume: 13,141
  • Bid/Ask: 26.61 / 26.61
  • Day's Range: 26.60 - 27.10
Pfizer 26.63 +0.65 +2.50%

NYSE:PFE Financials

 
A brief overview of the NYSE:PFE financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Pfizer over time.

Pfizer Inc. reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 2,067 million compared to USD 1,967 million a year ago. Revenue was USD 13,283 million compared to USD 13,007 million a year ago. Net income was USD 41 million compared to USD 2,327 million a year ago. Basic earnings per share from continuing operations was USD 0.01 compared to USD 0.41 a year ago. Diluted earnings per share from continuing operations was USD 0.01 compared to USD 0.41 a year ago. Basic earnings per share was USD 0.01 compared to USD 0.41 a year ago. Diluted earnings per share was USD 0.01 compared to USD 0.41 a year ago.For the six months, sales was USD 4,240 million compared to USD 4,028 million a year ago. Revenue was USD 28,162 million compared to USD 31,492 million a year ago. Net income was USD 3,156 million compared to USD 7,870 million a year ago. Basic earnings per share from continuing operations was USD 0.56 compared to USD 1.4 a year ago. Diluted earnings per share from continuing operations was USD 0.55 compared to USD 1.38 a year ago. Basic earnings per share was USD 0.56 compared to USD 1.4 a year ago. Diluted earnings per share was USD 0.55 compared to USD 1.38 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

PFE Income Statement

Gross margin TTM 60.16%
Operating margin TTM 5.95%
Net Profit margin TTM -4.7%
Return on Investment TTM 1.75%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 01, 2023
Total Revenue 13283 14878 14249 13232
Gross Profit 10515 11842 6982 4327
Operating Income 2975 4706 -1273 -2646
Net Income 41 3115 -3369 -2382

PFE Balance Sheet

Quick Ratio MRQ 0.42
Current Ratio MRQ 0.86
LT Debt to Equity MRQ 66%
Total Debt to Equity MRQ 79.66%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 01, 2023
Total Assets 216193 221095 226501 215021
Total Liabilities 128218 128537 137213 117817
Total Equity 87975 92558 89288 97204

PFE Cash Flow Statement

Cash Flow/Share TTM 1.41
Revenue/Share TTM 9.74
Operating Cash Flow  -4.06%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 01, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -1781 1090 5240
Cash From Investing Activities 4600 1732 -10996
Cash From Financing Activities -2459 -4931 5442
Net Change in Cash 343 -2137 -317
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PFE Comments

Write your thoughts about Pfizer Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
shortseller Best
shortseller Best Sep 01, 2024 7:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
People like to short more Pfizer because they know it will be difficult for the CEO to lead Pfizer to higher levels. Pfizer's stock price also hasn't moved higher since Chief Executive Albert Bourla took control of the company. thumbs 👇
Mo Ali
Av8er31 Sep 01, 2024 7:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
because they are not a growth company at the moment. but a dividend play rath
Shawn Aslani
Shawn Aslani Aug 27, 2024 11:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This what happens to PFE when a veterinarian manages a hundred plus years old company
shortseller Best
shortseller Best Aug 20, 2024 7:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
so many people short Pfizer. that is the easiest way to make money.
George Galloway
George Galloway Aug 08, 2024 3:37PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A few positive days and now back to normal.
Aket Orem
Aket Orem Jul 30, 2024 10:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is crazy i’m buyin more
Egbu Victor
Egbu Victor Jul 30, 2024 9:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
We are heading to $33.21 🤑🤑🤑
Aa Ro
Aa Ro Jul 30, 2024 9:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when and why, pls?
Egbu Victor
Egbu Victor Jul 30, 2024 9:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PFT to the moon 🤑🤑🤑🤑
shortseller Best
shortseller Best Jul 30, 2024 8:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good news = short sale. 28 is coming....
Péter Dovák
Péter Dovák Jul 30, 2024 6:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Egbu Victor
Egbu Victor Jul 26, 2024 12:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong Buy! +$50 coming soon
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email